Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: A randomized controlled pilot study

Journal of Hepatology

Volumn 37, Issue 4, 2002, Pages 448-455

  Spahr, Laurent ^a   Rubbia Brandt, Laura ^a   Frossard, Jean Louis ^a   Giostra, Emile ^a   Rougemont, Anne Laure ^a   Pugin, Jérôme ^a   Fischer, Maria ^b   Egger, Hanspeter ^b   Hadengue, Antoine ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b Essex Chemie AG   (Switzerland)

Author keywords

Apoptosis; Cytokine; Maddrey's score; Tolerance; Transvenous liver biopsy

Indexed keywords

BILIRUBIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; PREDNISONE; PROTHROMBIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ALCOHOL LIVER DISEASE; APOPTOSIS; ARTICLE; BACTERIAL PERITONITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FAILURE; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN ABSCESS; ADULT; AGED; BIOPSY; DRUG COMBINATION; FEMALE; HOSPITALIZATION; MALE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; APOPTOSIS; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS, ALCOHOLIC; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISONE; SEVERITY OF ILLNESS INDEX;

EID: 0036784414     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00230-1     Document Type: Article

References (41)

1. Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992;326:507-512.
2. Hardison WG, Lee FI. Prognosis in the acute disease of alcoholic patients. N Engl J Med 1966;275:61-66.
3. International group. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981;1:707-711.
4. Plümpe J, Streetz K. Manns MP, Trautwein C. Tumour necrosis factor alpha-mediator of apotosis and cell proliferation of hepatocytes. Ital J Gastroenterol Hepatol 1999;31:235-243.
5. Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 1993;21:112-116.
6. Maher JJ. Cytokines: overview. Sem Liver Dis 1999;19:109-115.
7. Urbaschek R, McCuskey RS, Rudi V, Becker KP, Stickel F, Urbaschek B, et al. Endotoxin, endotoxin-neutralizing capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. Alcohol Clin Exp Res 2001;25:261-268.
8. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, et al. Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-952.
9. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Sem Liver Dis 1999;19:205-219.
10. Burra P, Hubscher SG, Shaw J, Elias E, Adams DH. Is the intercellular adhesion molecule-1/leukocyte function associated antigen 1 pathway of leukocyte adhesion involved in the tissue damage of alcoholic hepatitis? Gut 1992;33:268-271.
11. Spahr L, Rubbia-Brandt L, Pugin J, Giostra E, Frossard JL, Borisch B, et al. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol 2001;35:582-589.
12. Bradham CA, Plümpe J, Manns MP, Brenner DA, Trautwein C. Mechanisms of hepatic toxicity: TNF-induced liver injury. Am J Physiol 1998;275:G387-G392.
13. Khoruts A, Stahnke L, McClain C, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991;13:267-276.
14. Ziol M, Tepper M, Lohez M, Arcangeli G, Ganne N, Christidis C, et al. Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis. J Hepatol 2001;34:254-260.
15. Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, Gores GJ. Hepatocyte apoptosis is a pathological feature of human alcoholic hepatitis. J Hepatol 2001;34:248-253.
16. Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong HF, Veech GA, et al. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990;14:255-259.
17. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112:917-920.
18. Fujimoto M, Uemura M, Nakatani Y, Tsujita S, Hoppo K, Tamagawa T, et al. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relationship to severity of liver disturbance. Alcohol Clin Exp Res 2000;24:48S-54S.
19. Maddrey WC, Boinott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-199.
20. Carithers RL, Herlong F, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989;110:685-690.
21. Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36:480-487.
22. Taïeb J, Mathurin P, Elbim C, Cluzel P, Arce-Vicioso M, Bernard B, et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol 2000;32:579-586.
23. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-1939.
24. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistula in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405.
25. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor α antibody (Infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-28.
26. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-729.
27. Lankarani KB. Mortality associated with infliximab (letter). J Clin Gastroenterol 2001;33:255-256.
28. Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997;26:1530-1537.
29. Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou JP. Transvenous liver biopsy. An experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology 1982;83:338-340.
30. Schwab M, Klotz U. Pharmacokinetics considerations in the treatment of inflammatory bowel diseases. Clin Pharmacokinet 2001;40:723-751.
31. Tavassoli M, Shaklai M, Crosby WH. Cytochemical diagnosis of acute myelomonocytic leukemia. Am J Clin Pathol 1979;72:59-62.
32. Wuthrich RP, Jevnikar AM, Takei F, Glimcher LH, Kelley VE. Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated in autoimmune murine nephritis. Am J Pathol 1990;136:441-450.
33. Volpes R, Van den Oord JJ, Desmet VJ. Immunohistochemical study of adhesion molecules in liver inflammation. Hepatology 1990;12:59-65.
34. Douds AC, Guan Lim A, Jazrawi RP, Finlayson C, Maxwell JD. Serum intercellular adhesion molecule-I in alcoholic liver disease and its relationship with histological disease severity. J Hepatol 1997;26:280-286.
35. Huang YS, Chan CY, Wu JC, Pai CH, Chao Y, Lee SD. Serum levels of interleukin-8 in alcoholic liver disease: relationship with disease stage, biochemical parameters and survival. J Hepatol 1996;24:377-384.
36. Hill DB, Marsano L, Cohen D, Allen J, Shedlofsky S, McClain CJ. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992;119:547-552.
37. Hill DB, Marsano LS, McClain CJ. Increased plasma interleukin-8 concentrations in alcoholic hepatitis. Hepatology 1993;18:576-580.
38. Barrera P, Joosten LAB, den Broeder AA, van de Putte LBA, van Riel PLCM, van den Berg WB. Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin-1 and TNFα in patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:660-669.
39. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-1476.
40. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 1991;13:364-375.
41. Navasa M, Fernandez J, Rodes J. Bacterial infections in liver cirrhosis. Ital J Gastroenterol Hepatol 1999;31:616-625.